PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols

被引：0

作者：

Rigo L. ^{[1
]}

de Bona Pessoa D. ^{[1
]}

Borges A.C. ^{[1
]}

da Cunha P.G. ^{[1
]}

Vargas F.R. ^{[2
]}

机构：

[1] Department of Nuclear Medicine, Hospital Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, 769 - Bela Vista, São Paulo, CEP: 01323-001, SP

[2] Department of Radiology, Hospital Beneficência Portuguesa de São Paulo, Rua Maestro Cardim, 769 - Bela Vista, São Paulo, CEP: 01323-001, SP

来源：

Current Radiology Reports | / 4卷 / 12期

关键词：

Molecular imaging; PET–CT; Positron emission tomography; Prostate cancer; PSMA ligand;

D O I：

10.1007/s40134-016-0189-1

中图分类号：

学科分类号：

摘要：

The detection of lesions in the context of biochemical recurrence of prostate cancer is a major challenge for all imaging modalities. Recently, the prostate-specific membrane antigen (PSMA) is recognized as a novel target for the PET–CT (positron emission tomography–computed tomography) imaging of prostate cancer with the tracer 68 Ga-PSMA ( 68 Gallium-labelled PSMA), mainly in the detection of relapses and metastasis. PSMA PET–CT imaging shows high tracer uptake at the sites of primary tumor and lymph node, and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET–CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence, and it proved to be clearly superior in detecting prostate cancer lesions at low PSA levels when compared to other methods. © 2016, Springer Science+Business Media New York.

引用

共 25 条

[1]

Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2015, CA Cancer J Clin, 65, pp. 5-29, (2015)

[2]

Kabasakal L., AbuQbeitah M., Aygun A., Yeyin N., Ocak M., Demirci E., Toklu T., Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer, Eur J Nucl Med Mol Imaging, 42, 13, pp. 1976-1983, (2015)

[3]

Ghosh A., Heston W.D., Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer, J Cell Biochem, 91, pp. 528-539, (2004)

[4]

Chang S.S., O'Keefe D.S., Bacich D.J., Reuter V.E., Heston W.D., Gaudin P.B., Prostate-specific membrane antigen is produced in tumor-associated neovasculature, Clin Cancer Res, 5, pp. 2674-2681, (1999)

[5]

Samplaski M.K., Heston W., Elson P., Magi-Galtuzzi C., Hansel D.E., Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature, Mod Pathol, 24, pp. 1521-1529, (2011)

[6]

Wang W., Tavora F., Sharma R., Eisenberger M., Netto G.J., PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma, Urol Oncol, 27, pp. 525-528, (2009)

[7]

Eur J Nucl Med Mol Imaging, (2013)

[8]

Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C., Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 1, pp. 81-85, (1997)

[9]

Eur J Nucl Med Mol Imaging, (2015)

[10]

Perner S., Hofer M.D., Kim R., Shah R.B., Li H., Moller P., Hautmann R.E., Gschwend J.E., Kuefer R., Rubin M.A., Prostate-specific membrane antigen expression as a predictor of prostate cancer progression, Hum Pathol, 38, pp. 696-701, (2007)

← 1 2 3 →